Ramaswamy Vivek's Form 4 filing
Roivant Sciences Ltd.ROIV · filed Dec 15, 2025
- Accession no.
- 0001635075-25-000006
- Filed
- Dec 15, 2025
- Trade date
- Dec 11-15, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 3 derivative transactions. Open-market sales total $67.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ramaswamy VivekCIK 0001635075 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Common Shares | MOption exerciseAcquired | +1,869,691 | $12.68 | +$23,707,681.88 | 35,523,447 | Direct | |
| Dec 11, 2025 | Common Shares | SSaleDisposed | −774,142 | $21.64F1 | −$16,752,432.88 | 34,749,305 | Direct | |
| Dec 11, 2025 | Common Shares | JOtherDisposed | −1,095,550 | $21.64F1 | −$23,707,702 | 33,653,755 | Direct | |
| Dec 12, 2025 | Common Shares | MOption exerciseAcquired | +4,672,724 | $12.68 | +$59,250,140.32 | 38,326,479 | Direct | |
| Dec 12, 2025 | Common Shares | SSaleDisposed | −1,975,858 | $21.96F3 | −$43,389,841.68 | 36,350,621 | Direct | |
| Dec 12, 2025 | Common Shares | JOtherDisposed | −2,696,866 | $21.96F3 | −$59,223,177.36 | 33,653,755 | Direct | |
| Dec 15, 2025 | Common Shares | MOption exerciseAcquired | +832,453 | $12.68 | +$10,555,504.04 | 34,486,208 | Direct | |
| Dec 15, 2025 | Common Shares | SSaleDisposed | −353,745 | $22.05F4 | −$7,800,077.25 | 34,132,463 | Direct | |
| Dec 15, 2025 | Common Shares | JOtherDisposed | −478,708 | $22.05F4 | −$10,555,511.4 | 33,653,755 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Common Stock | MOption exerciseDisposed | −1,869,691 | $0.00 | $0 | 27,655,404 | Direct | |
| Dec 12, 2025 | Common Stock | MOption exerciseDisposed | −4,672,724 | $0.00 | $0 | 22,982,680 | Direct | |
| Dec 15, 2025 | Common Stock | MOption exerciseDisposed | −832,453 | $0.00 | $0 | 22,150,227 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
Referenced by the price of 2 transactions in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive.
Referenced by the price of 2 transactions in Table I.